Long-term impact of clozapine and psychosocial treatment on psychiatric symptoms and cognitive functioning

Psychiatric Services

Volumn 47, Issue 1, 1996, Pages 41-45

  Grace, Jeffery ^a,b   Bellus, Stephen B ^a,b   Raulin, Michael L ^a,b   Herz, Marvin I ^d   Priest, Barbara L ^a   Brenner, Viktor ^c   Donnelly, Kerry ^e   Smith, Patricia ^a   Gunn, Susan ^a  

^a Buffalo Psychiatric Center   (United States)

^b Department of Psychiatry ^*

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITION; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; PATIENT CARE; PATIENT COMPLIANCE; PSYCHIATRIC DIAGNOSIS; PSYCHOSOCIAL DISORDER; SCHIZOPHRENIA;

EID: 0030028965     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.47.1.41     Document Type: Article

References (35)

1. Baldessarini RJ: Antipsychotic agents, in Chemotherapy in Psychiatry: Principles and Practice. Edited by Baldessarini RJ. Cambridge, Mass, Harvard University Press, 1985
2. Wilson WH: Clinical review of clozapine treatment in a state hospital Hospital and Community Psychiatry 43:700-703, 1992
3. Safferman A, Leiberman JA, Kane HM. et al: Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin 17.247-261, 1991
4. Honigfeld G, Patin J: A two-year clinical and economic follow-up of patients on clozapine. Hospital and Community Psychiatry 41:882-885, 1990
5. Meltzer HY, Burnett S, Bastani B. et al: Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry 41:892-897, 1990
6. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45:789-796, 1988
7. Cohen BM, Keck PE, Satlin A, et al. Prevalence and severity of akathisia in patients on clozapine. Biological Psychiatry 29:1215-1219, 1991
8. Devinsky O, Honigfeld G Patin J: Clozapine-related seizures. Neurology 41:369-371, 1991
9. Schmauss M, Wolff R, Erfurth A, et al: To-lerability of long-term clozapine treatment. Psychopharmacology 99(supp): 105-108, 1989
10. Gunther W, Baghai T, Naber D, et al: EEG alterations and seizures during treatment with clozapine. a retrospective study of 283 patients. Pharmacopsychiatry 26.69-74, 1993
11. Leiberman JA, Saltz BI, Johns CA, et al: The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry 158: 503-510, 1991
12. Nightingale SL: Approval of clozapine for refractory schizophrenia. JAMA 263:202, 1990
13. Kronig MH, Munne BA, Scymanski S, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. American Journal of Psychiatry 152.179-182, 1995
14. Hales RE, Yudofsky SC, Talbott JA: Textbook of Psychiatry, 2nd ed. Washington, DC, American Psychiatric Press, 1994
15. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed, rev. Washington, DC, American Psychiatric Association, 1987
16. Overall J, Gorman D. The Brief Psychiatric Rating Scale. Psychological Reports 10: 799-812, 1962
17. Guy W: Clinical Global Impressions Scale. ECDEU Assessment Manual for Pharmacology. DHHS pub (ADM) 76-338. Rockville, Md, National Institute of Mental Health, 1976
18. Abnormal Involuntary Movement Scale. DHEW pub (ADM) 9-117. Rockville, Md, National Institute of Mental Health, 1974
19. Yozawitz A: Applied neuropsychology in a psychiatric center, in Neuropsychological Assessment of Neuropsychiatric Disorders. Edited by Grant I, Adams K. New York, Oxford, 1986
20. Mendoza JE: Mental Status Examination. New Orleans, Veterans Affairs Medical Center, 1986
21. Army Individual Test Battery: Manual of Directions and Sconng. Washington, DC, War Department, Adjutant General's Office. 1944
22. Benton AL, Hamsher KD: Multilingual Aphasia Examination. Iowa City, University of Iowa, 1976
23. Goodglass H, Kaplan E: Assessment of Aphasia and Related Disorders. Philadelphia. Lea & Febiger, 1972
24. Wechsler DM WAIS-R Manual. New York, Psychological Corp, 1981
25. O'Connor FW, Sprunger JE, Petry SD: A clozapine treatment program for patients living in the community. Hospital and Community Psychiatry 43:909-911, 1992
26. Herz MI, Grace J, Treanor JJ, et al: Impact of clozapine on clinical and cognitive functioning in treatment-refractory schizophrenics at the Buffalo Psychiatric Center. Presented at the annual research conference of the New York State Office of Mental Health, Albany, Dec 1990
27. Miller DD, Perry, PJ, Cadoret RJ, et al: Clozapine's effect on negative symptoms in treatment-refractory schizophrenia. Comprehensive Psychiatry 35:8-15, 1994
28. Hagger C, Buckley P, Kenny JT, et al: Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry 34:702-712, 1993
29. Goldberg TE, Weinberger DR: The effect of clozapine on neurocognition: an overview. Journal of Clinical Psychiatry 55(Sept suppl B):88-90, 1994
30. Lee MA, Thompson PA, Meltzer HY: Effects of clozapine on cognitive function in schizophrenia. Journal of Clinical Psychiatry 55(Sept suppl B):82-87, 1994
31. Meltzer HY: Dimensions of outcome with clozapine. British Journal of Psychiatry 160.46-53, 1992
32. Clozapine Study Group: The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. British Journal of Psychiatry 163:150-154, 1993
33. Griffith EEH: Clozapine: problems for the public sector. Hospital and Community Psychiatry 41:837, 1990
34. Peck C: FDA's position on the Clozaril Patient Management System. Hospital and Community Psychiatry 41:876-877, 1990
35. Reid WH: Access to care: clozapine in the public sector. Hospital and Community Psychiatry 41.870-873, 1990